Acetylation discriminates disease-specific tau deposition.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
22 09 2023
Historique:
received: 09 01 2023
accepted: 14 09 2023
medline: 25 9 2023
pubmed: 23 9 2023
entrez: 22 9 2023
Statut: epublish

Résumé

Pathogenic aggregation of the protein tau is a hallmark of Alzheimer's disease and several other tauopathies. Tauopathies are characterized by the deposition of specific tau isoforms as disease-related tau filament structures. The molecular processes that determine isoform-specific deposition of tau are however enigmatic. Here we show that acetylation of tau discriminates its isoform-specific aggregation. We reveal that acetylation strongly attenuates aggregation of four-repeat tau protein, but promotes amyloid formation of three-repeat tau. We further identify acetylation of lysine 298 as a hot spot for isoform-specific tau aggregation. Solid-state NMR spectroscopy demonstrates that amyloid fibrils formed by unmodified and acetylated three-repeat tau differ in structure indicating that site-specific acetylation modulates tau structure. The results implicate acetylation as a critical regulator that guides the selective aggregation of three-repeat tau and the development of tau isoform-specific neurodegenerative diseases.

Identifiants

pubmed: 37739953
doi: 10.1038/s41467-023-41672-1
pii: 10.1038/s41467-023-41672-1
pmc: PMC10517010
doi:

Substances chimiques

14-3-3 Proteins 0
tau Proteins 0
MAPT protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5919

Informations de copyright

© 2023. Springer Nature Limited.

Références

Dugger, B. N. & Dickson, D. W. Pathology of neurodegenerative diseases. Cold Spring Harb. Perspect. Biol. 9, https://doi.org/10.1101/cshperspect.a028035 (2017).
Wang, Y. & Mandelkow, E. Tau in physiology and pathology. Nat. Rev. Neurosci. 17, 5–21 (2016).
pubmed: 26631930
Shi, Y. et al. Structure-based classification of tauopathies. Nature 598, 359–363 (2021).
pubmed: 34588692 pmcid: 7611841
Li, D. & Liu, C. Hierarchical chemical determination of amyloid polymorphs in neurodegenerative disease. Nat. Chem. Biol. 17, 237–245 (2021).
pubmed: 33432239
Andreadis, A. Misregulation of tau alternative splicing in neurodegeneration and dementia. Prog. Mol. Subcell. Biol. 44, 89–107 (2006).
pubmed: 17076266
Ghetti, B. et al. Invited review: Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging. Neuropathol. Appl. Neurobiol. 41, 24–46 (2015).
pubmed: 25556536 pmcid: 4329416
Goedert, M. & Jakes, R. Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization. EMBO J. 9, 4225–4230 (1990).
pubmed: 2124967 pmcid: 552204
Falcon, B. et al. Structures of filaments from Pick’s disease reveal a novel tau protein fold. Nature 561, 137–140 (2018).
pubmed: 30158706 pmcid: 6204212
Alquezar, C., Arya, S. & Kao, A. W. Tau post-translational modifications: dynamic transformers of tau function, degradation, and aggregation. Front. Neurol. 11, 595532 (2020).
pubmed: 33488497
Min, S. W. et al. Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat. Med. 21, 1154–1162 (2015).
pubmed: 26390242 pmcid: 4598295
Chen, X. et al. Promoting tau secretion and propagation by hyperactive p300/CBP via autophagy-lysosomal pathway in tauopathy. Mol. Neurodegener. 15, 2 (2020).
pubmed: 31906970 pmcid: 6945522
Schueller, E. et al. Dysregulation of histone acetylation pathways in hippocampus and frontal cortex of Alzheimer’s disease patients. Eur. Neuropsychopharmacol. 33, 101–116 (2020).
pubmed: 32057591
Arakhamia, T. et al. Posttranslational modifications mediate the structural diversity of tauopathy strains. Cell 180, 633–644 e612 (2020).
pubmed: 32032505 pmcid: 7491959
Kametani, F. et al. Comparison of common and disease-specific post-translational modifications of pathological Tau associated with a wide range of tauopathies. Front. Neurosci. 14, 581936 (2020).
pubmed: 33250706 pmcid: 7672045
Caballero, B. et al. Acetylated tau inhibits chaperone-mediated autophagy and promotes tau pathology propagation in mice. Nat. Commun. 12, 2238 (2021).
pubmed: 33854069 pmcid: 8047017
Alquezar, C. et al. TSC1 loss increases risk for tauopathy by inducing tau acetylation and preventing tau clearance via chaperone-mediated autophagy. Sci. Adv. 7, eabg3897 (2021).
pubmed: 34739309 pmcid: 8570595
Shin, M. K. et al. Reducing acetylated tau is neuroprotective in brain injury. Cell 184, 2715–2732 e2723 (2021).
pubmed: 33852912 pmcid: 8491234
Constantinidis, J., Richard, J. & Tissot, R. Pick’s disease. Histological and clinical correlations. Eur. Neurol. 11, 208–217 (1974).
pubmed: 4137107
Chakraborty, P. et al. Co-factor-free aggregation of tau into seeding-competent RNA-sequestering amyloid fibrils. Nat. Commun. 12, 4231 (2021).
pubmed: 34244499 pmcid: 8270918
Jicha, G. A., Bowser, R., Kazam, I. G. & Davies, P. Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J. Neurosci. Res. 48, 128–132 (1997).
pubmed: 9130141
Cohen, T. J., Friedmann, D., Hwang, A. W., Marmorstein, R. & Lee, V. M. The microtubule-associated tau protein has intrinsic acetyltransferase activity. Nat. Struct. Mol. Biol. 20, 756–762 (2013).
pubmed: 23624859
Cohen, T. J., Constance, B. H., Hwang, A. W., James, M. & Yuan, C. X. Intrinsic Tau acetylation is coupled to auto-proteolytic Tau fragmentation. PLoS ONE 11, e0158470 (2016).
pubmed: 27383765 pmcid: 4934699
Weingarten, M. D., Lockwood, A. H., Hwo, S. Y. & Kirschner, M. W. A protein factor essential for microtubule assembly. Proc. Natl Acad. Sci. USA 72, 1858–1862 (1975).
pubmed: 1057175 pmcid: 432646
Gustke, N., Trinczek, B., Biernat, J., Mandelkow, E. M. & Mandelkow, E. Domains of tau protein and interactions with microtubules. Biochemistry 33, 9511–9522 (1994).
pubmed: 8068626
Kellogg, E. H. et al. Near-atomic model of microtubule-tau interactions. Science 360, 1242–1246 (2018).
pubmed: 29748322 pmcid: 6225777
Irwin, D. J. et al. Acetylated tau, a novel pathological signature in Alzheimer’s disease and other tauopathies. Brain 135, 807–818 (2012).
pubmed: 22366796 pmcid: 3286338
Irwin, D. J. et al. Acetylated tau neuropathology in sporadic and hereditary tauopathies. Am. J. Pathol. 183, 344–351 (2013).
pubmed: 23885714 pmcid: 3730769
Trzeciakiewicz, H. et al. An HDAC6-dependent surveillance mechanism suppresses tau-mediated neurodegeneration and cognitive decline. Nat. Commun. 11, 5522 (2020).
pubmed: 33139698 pmcid: 7606452
Gorsky, M. K., Burnouf, S., Dols, J., Mandelkow, E. & Partridge, L. Acetylation mimic of lysine 280 exacerbates human Tau neurotoxicity in vivo. Sci. Rep. 6, 22685 (2016).
pubmed: 26940749 pmcid: 4778021
Fujimoto, H. et al. A possible overestimation of the effect of acetylation on lysine residues in KQ mutant analysis. J. Comput. Chem. 33, 239–246 (2012).
pubmed: 22072565
Chalker, J. M., Lercher, L., Rose, N. R., Schofield, C. J. & Davis, B. G. Conversion of cysteine into dehydroalanine enables access to synthetic histones bearing diverse post-translational modifications. Angew. Chem. Int. Ed. Engl. 51, 1835–1839 (2012).
pubmed: 22247073
Bhattacharya, K., Rank, K. B., Evans, D. B. & Sharma, S. K. Role of cysteine-291 and cysteine-322 in the polymerization of human tau into Alzheimer-like filaments. Biochem. Biophys. Res. Commun. 285, 20–26 (2001).
pubmed: 11437366
Spillantini, M. G. & Goedert, M. Tau pathology and neurodegeneration. Lancet Neurol. 12, 609–622 (2013).
pubmed: 23684085
Min, S. W. et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 67, 953–966 (2010).
pubmed: 20869593 pmcid: 3035103
Cohen, T. J. et al. The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat. Commun. 2, 252 (2011).
pubmed: 21427723
Tracy, T. E. et al. Acetylated Tau obstructs KIBRA-mediated signaling in synaptic plasticity and promotes tauopathy-related memory loss. Neuron 90, 245–260 (2016).
pubmed: 27041503 pmcid: 4859346
Sohn, P. D. et al. Acetylated tau destabilizes the cytoskeleton in the axon initial segment and is mislocalized to the somatodendritic compartment. Mol. Neurodegener. 11, 47 (2016).
pubmed: 27356871 pmcid: 4928318
Zhang, W. et al. Novel tau filament fold in corticobasal degeneration. Nature 580, 283–287 (2020).
pubmed: 32050258 pmcid: 7148158
Xiang, X. et al. Role of molecular polymorphism in defining tau filament structures in neurodegenerative diseases. Preprint at bioRxiv https://doi.org/10.1101/2021.05.24.445353 (2021).
Mukrasch, M. D. et al. Sites of tau important for aggregation populate beta-structure and bind to microtubules and polyanions. J. Biol. Chem. 280, 24978–24986 (2005).
pubmed: 15855160
Mukrasch, M. D. et al. Structural polymorphism of 441-residue tau at single residue resolution. PLoS Biol. 7, e34 (2009).
pubmed: 19226187
Narayanan, R. L. et al. Automatic assignment of the intrinsically disordered protein Tau with 441-residues. J. Am. Chem. Soc. 132, 11906–11907 (2010).
pubmed: 20687558
Kamah, A. et al. Nuclear magnetic resonance analysis of the acetylation pattern of the neuronal Tau protein. Biochemistry 53, 3020–3032 (2014).
pubmed: 24708343
Barbet-Massin, E. et al. Rapid proton-detected NMR assignment for proteins with fast magic angle spinning. J. Am. Chem. Soc. 136, 12489–12497 (2014).
pubmed: 25102442 pmcid: 4156866
Vranken, W. F. et al. The CCPN data model for NMR spectroscopy: development of a software pipeline. Proteins 59, 687–696 (2005).
pubmed: 15815974
Fitzpatrick, A. W. P. et al. Cryo-EM structures of tau filaments from Alzheimer’s disease. Nature 547, 185–190 (2017).
pubmed: 28678775 pmcid: 5552202

Auteurs

Pijush Chakraborty (P)

German Center for Neurodegenerative Diseases (DZNE), Von-Siebold-Str. 3a, 37075, Göttingen, Germany.

Gwladys Rivière (G)

German Center for Neurodegenerative Diseases (DZNE), Von-Siebold-Str. 3a, 37075, Göttingen, Germany.

Alina Hebestreit (A)

German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.

Alain Ibáñez de Opakua (AI)

German Center for Neurodegenerative Diseases (DZNE), Von-Siebold-Str. 3a, 37075, Göttingen, Germany.

Ina M Vorberg (IM)

German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany.

Loren B Andreas (LB)

Department for NMR-based Structural Biology, Max Planck Institute for Multidisciplinary Sciences, Am Faßberg 11, 37077, Göttingen, Germany.

Markus Zweckstetter (M)

German Center for Neurodegenerative Diseases (DZNE), Von-Siebold-Str. 3a, 37075, Göttingen, Germany. markus.zweckstetter@dzne.de.
Department for NMR-based Structural Biology, Max Planck Institute for Multidisciplinary Sciences, Am Faßberg 11, 37077, Göttingen, Germany. markus.zweckstetter@dzne.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH